Bayer's $7.25 Billion Roundup Settlement Goes Before Missouri Court as Pharma Pipeline Delivers Two FDA Wins
核心洞察
Bayer (搜索)'s Monsanto (搜索) unit appeared before a Missouri state court seeking final approval of a $7.25 billion settlement covering roughly 65,000 Roundup (搜索) claims alleging non-Hodgkin lymphoma (搜索).
Judge Timothy Boyer of the Missouri Circuit Court (搜索) in St. Louis heard objections from plaintiffs' attorneys who argue the deal blocks claimants from taking their cases to trial.
The settlement follows a June Supreme Court (搜索) ruling that FIFRA preempts state failure-to-warn claims where the EPA (搜索) has confirmed product safety.
Bayer (搜索)'s Monsanto (搜索) unit appeared before a Missouri state court on Monday seeking final approval of a $7.25 billion settlement intended to resolve tens of thousands of U.S. lawsuits claiming that its Roundup (搜索) weedkiller causes cancer. Judge Timothy Boyer of the Missouri Circuit Court (搜索) in St. Louis is examining the terms of the deal and considering objections from some plaintiffs' attorneys who argue the settlement pushes their clients into a framework against their interests. Boyer is not expected to issue an immediate ruling at the hearing.
Bayer (搜索) announced the proposed settlement in February. The company says the deal is designed to resolve current and future Roundup (搜索) claims alleging non-Hodgkin lymphoma (搜索) injuries. Bayer faces approximately 65,000 claims in U.S. state and federal courts. Individual awards under the settlement would fall between $10,000 and $165,000, with the precise amount tied to factors including disease severity, the claimant's age when diagnosed, and the setting in which they encountered the herbicide.
A company spokesman said in a statement that "Monsanto (搜索) continues to believe the class settlement, which is supported by plaintiffs' counsel representing tens of thousands of potential class members, is fair to all parties and warrants final approval." Critics of the deal argue it falls short financially and that its terms effectively block current and future claimants who want to take their cases to trial.
Procedural Path to the Hearing
The hearing follows a series of legal and procedural developments. The Eighth Circuit Court of Appeals (搜索) dismissed objectors' attempt to move the settlement decision to a federal court on August 27, leaving jurisdiction in Missouri intact. Judge Boyer rescheduled the final approval hearing to September 14 after a joint motion by Monsanto (搜索) and class counsel in early August.
The litigation dates to a 2015 determination by the World Health Organization's International Agency for Research on Cancer that glyphosate was a probable carcinogen. The EPA (搜索) has consistently found that glyphosate is not likely to cause cancer in humans, and the agency says an updated human health risk assessment is expected to be completed in late 2026. Bayer (搜索) rejects the allegations, pointing to what it describes as an extensive body of scientific research concluding that glyphosate does not cause cancer.
Supreme Court Preemption Ruling Reshapes the Claims Landscape
In June, the Supreme Court (搜索) ruled 7-2 that the Federal Insecticide, Fungicide, and Rodenticide Act expressly preempts state-law failure-to-warn claims when the EPA (搜索) has made a definitive determination on product safety. The decision undercut a central legal theory in thousands of pending Roundup (搜索) cases. The ruling came in the case of John Durnell, a St. Louis-area man who developed non-Hodgkin lymphoma (搜索) after roughly two decades of applying Roundup to neighborhood parks.
Two FDA Approvals on the Pharma Side
The legal proceeding comes as Bayer (搜索)'s pharmaceutical division has secured a pair of U.S. regulatory green lights. Sevabertinib (搜索) received accelerated approval as a first-line therapy for certain forms of lung cancer (搜索). That accelerated pathway carries continued-approval conditions: the drug's authorization hinges on confirmatory clinical data, and should follow-up studies disappoint, its addressable patient population could narrow.
Kerendia, known chemically as finerenone, won an expanded indication for chronic kidney disease (搜索) in adults with type 1 diabetes (搜索), targeting a reduction in albuminuria. The label extension rests on data from the Phase III FINE-ONE trial, which enrolled 242 patients over six months. The drug cut the urine albumin-to-creatinine ratio by 34%, against 12% for placebo, a 25-percentage-point edge over the dummy treatment. Safety data showed hyperkalemia in 10.1% of participants versus 3.3% on placebo, though therapy-related discontinuations stayed low at 1.7%.
It marks the first new treatment option for chronic kidney disease (搜索) in type 1 diabetes (搜索) in three decades, and Bayer (搜索) has guided toward peak annual sales exceeding EUR 3 billion for the drug. Group revenue in the second quarter of 2026 came in at EUR 10.87 billion, only modestly ahead of the prior-year EUR 10.74 billion.
Commercial and Reimbursement Considerations
Kerendia's uptake depends on reimbursement decisions from health insurers, and the need for regular potassium monitoring may make some physicians hesitant to start therapy early. In the US, drug-pricing initiatives advanced under the Inflation Reduction Act are adding pressure on reimbursement rates for modern therapies, and restrictive formulary placement could leave sales growth short of expectations.
Bayer (搜索) publishes its interim report for the third quarter on 3 November 2026. That report will show how much of the pharma momentum is flowing through to the numbers, and whether full-year targets remain on track.